Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Finance
Passage Bio will cut jobs to save money
by Michael McCoy
March 19, 2022
| A version of this story appeared in
Volume 100, Issue 10
Passage Bio, a gene therapy start-up cofounded in 2019 by University of Pennsylvania scientist James Wilson, is cutting about 13% of its workforce as part of a plan to conserve cash. At the end of 2021 the company had 133 employees, 85 of whom were in R&D or technical roles. The firm’s chief R&D officer, Eliseo O. Salinas, will also leave. Passage has three gene therapies in clinical trials for central nervous system disorders, including frontotemporal dementia.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X